Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2021
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin,Clopidogrel,Rosuvastatin Calcium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr Reddy’s Launches Rozat Gold FDC in India (Aspirin, Rosuvastatin, Clopidogrel)
Details : Rozat Gold is a fixed dose combination medicine consisting aspirin, rosuvastatin & clopidogrel. It is indicated for the treatment of coronary artery diseases.
Product Name : Rozat Gold
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2021
Lead Product(s) : Aspirin,Clopidogrel,Rosuvastatin Calcium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Indication for Plavix® (clopidogrel) Now Approved in the European Union
Details : Plavix (clopidogrel) is a P2Y12 platelet inhibitor which is indicated for the treatment of in adult patients with moderate to high-risk transient ischemic attack.
Product Name : Plavix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2021
Lead Product(s) : Clopidogrel,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2012
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2012
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2012
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2012
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2010
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2010
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2010
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable